Pliant Therapeutics Inc
(STU:9PT)
€
13.3
0.4 (3.05%)
Market Cap: 833.15 Mil
Enterprise Value: 487.01 Mil
PE Ratio: 0
PB Ratio: 2.23
GF Score: 35/100 
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023 / 05:35PM GMT
Release Date Price:
€20
(-0.99%)
Brian Abrahams
RBC Capital Markets - Analyst
I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. Our next presenting company is Pliant Therapeutics. I'm very pleased to have their CFO, Keith Cummings; and their Chief Medical Officer, Ãric Lefebvre. So Keith and Eric, thanks again.
Ã;ric Lefebvre
Pliant Therapeutics, Inc. - Chief Medical Officer
Thank you.
Keith Cummings
Pliant Therapeutics, Inc. - CFO
Thank you.
Questions & Answers
Brian Abrahams
RBC Capital Markets - Analyst
So maybe just kicking things off, you guys recently presented some updated data for bexo and your Phase 2 IPF study. Can you maybe just run us through the key highlights from that data, maybe the Phase 2 overall and then the six-month data at the 320-mg dose that I think has been the most recent data you have talked about.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers